J Tamaoki, K Kohri, K Isono, A Nagai. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Adenocarcinoma, Bronchiolo-Alveolar/drug therapyAdenocarcinoma, Bronchiolo-Alveolar/metabolismAdenocarcinoma, Bronchiolo-Alveolar/pathologyAdministration, InhalationCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase Inhibitors/administration & dosageDNA Primers/chemistryHumansIndomethacin/administration & dosageIsoenzymes/drug effectsIsoenzymes/geneticsIsoenzymes/metabolismLung Neoplasms/drug therapyLung Neoplasms/metabolismLung Neoplasms/pathologyMembrane ProteinsPeroxidases/drug effectsPeroxidases/geneticsPeroxidases/metabolismProstaglandin-Endoperoxide Synthases/drug effectsProstaglandin-Endoperoxide Synthases/geneticsProstaglandin-Endoperoxide Synthases/metabolismRNA, Messenger/analysisSputum/metabolismTreatment Outcome
Substances： See more » Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDNA PrimersIsoenzymesMembrane ProteinsRNA, MessengerPeroxidasesCyclooxygenase 2PTGS2 protein, humanProstaglandin-Endoperoxide SynthasesIndomethacin
Year: 2000 PMID： 10767270 DOI： 10.1378/chest.117.4.1213
Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410